Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Submitted-evidence log — page 2

Third-party data submitted to the Institute, what was submitted, by whom, and whether it was used. Data submitted and not used are recorded with the reason.

Submissions

74 documents · page 2 of 3

Table 1. Evidence submissions on this page, in date order.

ReferenceReceivedWhat was submittedConcerningSubmitted byOutcome
CEI-SE/04914 Feb 2025Regulatory assessment documentA published review document from a competent authority.NAD+ (nicotinamide adenine dinucleotide)Dr Florentin VercingetorixUnder assessment
CEI-SE/03501 Feb 2025Third-party analytical reportA certificate or report from an independent laboratory.RetatrutideHamish IngelbrechtUsed — cited in a document
CEI-SE/02919 Dec 2024Certificate of analysisA supplier-issued certificate, submitted for assessment against the minimum data standard.EpithalonDr Zsuzsanna AchterbergUnder assessment
CEI-SE/02206 Nov 2024Photographic record of a presentationImages of labelling, packaging or a vial as received.OrforglipronDr Wendeline Haverkamp-DialloNot used — could not be de-identified
CEI-SE/00705 Nov 2024Batch documentationManufacturing or release documentation for a named batch.CagrilintideDr Henrike Møllerup-AdeyemiNot used — outside scope
CEI-SE/06411 Oct 2024Correspondence with a supplierA documented exchange bearing on a dossier.CagriSema (cagrilintide with semaglutide)Dr Verena UttridgeNot used — provenance not establishable
CEI-SE/03911 Sep 2024Batch documentationManufacturing or release documentation for a named batch.SemaglutideFlorentin JerninghamUsed — cited in a document
CEI-SE/03302 Sep 2024Photographic record of a presentationImages of labelling, packaging or a vial as received.AOD-9604Dr Brigitta Kaltenbach-MensahNot used — provenance not establishable
CEI-SE/01629 Aug 2024Certificate of analysisA supplier-issued certificate, submitted for assessment against the minimum data standard.ExenatideDr Benedikt Ellsworth-VanceUnder assessment
CEI-SE/04319 Aug 2024Unpublished trial dataData from a trial not fully reported in the literature.TesamorelinDr Evander Gwynne-SarpongUsed — informed an assessment without citation
CEI-SE/06603 Aug 2024Photographic record of a presentationImages of labelling, packaging or a vial as received.Melanotan-IIDr Wendeline Haverkamp-DialloNot used — could not be de-identified
CEI-SE/06304 Jul 2024Third-party analytical reportA certificate or report from an independent laboratory.Semaglutide, oralDr Brigitta ZetterlundUsed — informed an assessment without citation
CEI-SE/01129 Jun 2024Correspondence with a supplierA documented exchange bearing on a dossier.PT-141 (bremelanotide)Dr Ciarán Jankowiak-OseiNot used — provenance not establishable
CEI-SE/06925 Jun 2024Batch documentationManufacturing or release documentation for a named batch.IGF-1 LR3Ulysses UbertiniNot used — outside scope
CEI-SE/05424 Jun 2024Certificate of analysisA supplier-issued certificate, submitted for assessment against the minimum data standard.MazdutideDr Odalys LindeqvistUnder assessment
CEI-SE/03214 Jun 2024Batch documentationManufacturing or release documentation for a named batch.PetrelintideJolanta Beauchamp-EkongNot used — outside scope
CEI-SE/01423 May 2024Unpublished trial dataData from a trial not fully reported in the literature.SemaxDr Wojciech Oyelaran-SteenNot used — outside scope
CEI-SE/02111 May 2024Unpublished trial dataData from a trial not fully reported in the literature.LiraglutideDr Theodora QuennevilleNot used — outside scope
CEI-SE/03025 Apr 2024Unpublished trial dataData from a trial not fully reported in the literature.MOTS-cTamsin Fairweather-DuruUsed — cited in a document
CEI-SE/05628 Mar 2024Regulatory assessment documentA published review document from a competent authority.CagriSema (cagrilintide with semaglutide)Dr Odalys Kirkpatrick-OlaUnder assessment
CEI-SE/05126 Mar 2024Third-party analytical reportA certificate or report from an independent laboratory.GHRP-2Tamsin Fairweather-DuruNot used — could not be de-identified
CEI-SE/02414 Mar 2024Certificate of analysisA supplier-issued certificate, submitted for assessment against the minimum data standard.TirzepatideHamish IngelbrechtUsed — cited in a document
CEI-SE/04422 Feb 2024Photographic record of a presentationImages of labelling, packaging or a vial as received.HexarelinBenedikt HollingworthNot used — provenance not establishable
CEI-SE/07019 Feb 2024Certificate of analysisA supplier-issued certificate, submitted for assessment against the minimum data standard.GHK-CuDr Benedikt QuennevilleNot used — could not be de-identified
CEI-SE/00216 Feb 2024Regulatory assessment documentA published review document from a competent authority.SemaglutideDr Piotr AchterbergUsed — cited in a document
CEI-SE/06513 Feb 2024Unpublished trial dataData from a trial not fully reported in the literature.NAD+ (nicotinamide adenine dinucleotide)Dr Theodora QuennevilleNot used — outside scope
CEI-SE/05214 Dec 2023Photographic record of a presentationImages of labelling, packaging or a vial as received.SermorelinDr Zsuzsanna AchterbergNot used — outside scope
CEI-SE/04811 Dec 2023Regulatory assessment documentA published review document from a competent authority.ExenatideDr Emiliana Haverkamp-DialloUsed — cited in a document
CEI-SE/06106 Dec 2023Regulatory assessment documentA published review document from a competent authority.LixisenatideDr Evander Gwynne-SarpongUnder assessment
CEI-SE/00515 Nov 2023Unpublished trial dataData from a trial not fully reported in the literature.SurvodutideDr Wojciech Oyelaran-SteenUsed — informed an assessment without citation
Contributors consented to publication at the point of submission. The Institute publishes no submission from a person who did not consent to be named.

page 2 of 3

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.